Pheochromocytoma laboratory findings
|
Pheochromocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pheochromocytoma laboratory findings On the Web |
|
American Roentgen Ray Society Images of Pheochromocytoma laboratory findings |
|
Risk calculators and risk factors for Pheochromocytoma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Laboratory findings consistent with the diagnosis of pheochromocytoma include elevated 24-hour urinary fractionated catecholamines and metanephrines for low risk patients and plasma fractionated metanephrines for high risk ones.
Laboratory Findings
Diagnostic lab findings associated with pheochromocytoma include:
- Elevated plasma and urinary catecholamines and metanephrines
- Elevated urinary vanillyl mandelic acid
Indications of pheochromocytoma testing:[1]
- Triad of tachycardia, headache, and sweating.
- Episodes of palpitation, headache and tremors for unknown reasons.
- Hypertension at age <20 years), resistant hypertension.
- A family history of pheochromocytoma, , multiple endocrine neoplasia type 2, neurofibromatosis type 1, or von Hippel-Lindau.
- Presence of bilateral, extra-adrenal or multiple tumours or a malignant tumour, should be seen as indications for genetic testing.
- An incidentally discovered adrenal mass that does not have imaging characteristics consistent with pheochromocytoma.
High risk patients: plasma fractionated metanephrines is the first test, if elevated; 24-hour urinary fractionated metanephrines, catecholamines, and imaging shuld be the second test for diagnosis. [2]
High risk patients include: family history of MEN2 and VHL syndrome or past history of pheochromocytoma.
Low risk patients: 24-hour urinary fractionated catecholamines and metanephrines.[3]
NB: Discontinue TCAs two weeks before any hormonal assessments because they interrupt 24-hour urinary catecholamines metabolism.[4]
References
- ↑ Gimenez-Roqueplo AP, Lehnert H, Mannelli M, Neumann H, Opocher G, Maher ER; et al. (2006). "Phaeochromocytoma, new genes and screening strategies". Clin Endocrinol (Oxf). 65 (6): 699–705. doi:10.1111/j.1365-2265.2006.02714.x. PMID 17121518.
- ↑ Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P; et al. (2002). "Biochemical diagnosis of pheochromocytoma: which test is best?". JAMA. 287 (11): 1427–34. PMID 11903030.
- ↑ Sawka AM, Jaeschke R, Singh RJ, Young WF (2003). "A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines". J Clin Endocrinol Metab. 88 (2): 553–8. doi:10.1210/jc.2002-021251. PMID 12574179.
- ↑ Gimenez-Roqueplo AP, Lehnert H, Mannelli M, Neumann H, Opocher G, Maher ER; et al. (2006). "Phaeochromocytoma, new genes and screening strategies". Clin Endocrinol (Oxf). 65 (6): 699–705. doi:10.1111/j.1365-2265.2006.02714.x. PMID 17121518.